Showing results (111-120 of 125) with videos related to

Sort By:
Pageof 13
Communications Biology|November 13, 2022
Microfluidic live tracking and transcriptomics of cancer-immune cell doublets link intercellular proximity and gene regulationBianca C T Flores, Smriti Chawla, Ning Ma, et al.
BMC Genomics|January 8, 2017
The nature and nurture of cell heterogeneity: accounting for macrophage gene-environment interactions with single-cell RNA-SeqQuin F Wills, Esther Mellado-Gomez, Rory Nolan, et al.
Oral Oncology|September 24, 2017
A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141Naomi Kiyota, Yasuhisa Hasegawa, Shunji Takahashi, et al.
The Science of the Total Environment|December 28, 2020
Life cycle assessment of fish and seafood processed products - A review of methodologies and new challengesIsrael Ruiz-Salmón, Jara Laso, María Margallo, et al.
Blood|April 20, 2016
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MMAndrzej Jakubowiak, Massimo Offidani, Brigitte Pégourie, et al.
Cancer|June 28, 2019
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trialRobert Haddad, Fernando Concha-Benavente, George Blumenschein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2019
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab UseRobert L Ferris, Lisa Licitra, Jerome Fayette, et al.
The Oncologist|June 6, 2018
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck CancerMaura L Gillison, George Blumenschein, Jerome Fayette, et al.
Plos Pathogens|July 9, 2011
A role for TLR4 in Clostridium difficile infection and the recognition of surface layer proteinsAnthony Ryan, Mark Lynch, Sinead M Smith, et al.
Oral Oncology|June 10, 2018
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expressionRobert L Ferris, George Blumenschein, Jerome Fayette, et al.
Pageof 13